Drug Pricing
Commentary
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Drug Pricing
What We’re Watching – July 17
Rowena Itchon – 102-year-old woman survives 1918 pandemic, COVID-19 Gerri Schappals is 102, and survived the Spanish flu, cancer, and COVID-19 – an inspiration to us all. Ben Smithwick – The Black Swan Economy Jonathan Coslet, Senior Partner & Chief Investment Officer at TPG Capital, and Stanford Professor John B. ...
Commentary
Coronavirus drug cost – Ignore critics. Here’s why the price is right
Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Commentary
Learning The Right Lessons From The Race For An Effective Covid-19 Treatment
On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Commentary
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
Blog
What We’re Watching – June 19
Tim Anaya – How Medicines in the U.S. are Sold In the latest video in PRI’s “Escape the Drug Pricing Maze” video, the Professor and Pete reach the most difficult part of their journey: understanding how medicines are sold. It’s a complex system that hurts patients and at times exposes ...
Blog
What We’re Watching – June 5
Tim Anaya – Digging Up Ways to Lower Costs for High Value but Expensive Drugs In the latest video in the “Escape the Drug Pricing Maze” video, Sage the Detective Dog digs up clues on biologics and gene therapies – drugs that offer tremendous value for patients but are some ...
Agriculture
What We’re Watching – May 22
Rowena Itchon – A Memorial Day Tribute 2020 Kerry Jackson – This Doctor Won’t Take Health Insurance – and Charges Just $35 a Visit Meet the Pittsburgh doctor who doesn’t take health care insurance and charges only $35 for most office visits. That makes him a doctor from a different era. But ...
Blog
What We’re Watching – May 8
Rowena Itchon – Love in the Time of Coronavirus Watch some of our front line medical personnel battling COVID-19 and helping people stay alive take a much-needed break to recreate the iconic scene from Titanic, with an usual, personal protective equipment-themed twist. Kerry Jackson – Dorothy’s Song, COVID-19 Version Somewhere, ...
Coronavirus
Sally Pipes – The Push for Government-Run Health Care During the Coronavirus Crisis
PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies Sally C. Pipes is back to discuss some of the health care challenges that have popped up during the coronavirus crisis, including a renewed push for single-payer and calls for prescription drug price controls and a “Buy America” ...
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
What We’re Watching – July 17
Rowena Itchon – 102-year-old woman survives 1918 pandemic, COVID-19 Gerri Schappals is 102, and survived the Spanish flu, cancer, and COVID-19 – an inspiration to us all. Ben Smithwick – The Black Swan Economy Jonathan Coslet, Senior Partner & Chief Investment Officer at TPG Capital, and Stanford Professor John B. ...
Coronavirus drug cost – Ignore critics. Here’s why the price is right
Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Learning The Right Lessons From The Race For An Effective Covid-19 Treatment
On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
What We’re Watching – June 19
Tim Anaya – How Medicines in the U.S. are Sold In the latest video in PRI’s “Escape the Drug Pricing Maze” video, the Professor and Pete reach the most difficult part of their journey: understanding how medicines are sold. It’s a complex system that hurts patients and at times exposes ...
What We’re Watching – June 5
Tim Anaya – Digging Up Ways to Lower Costs for High Value but Expensive Drugs In the latest video in the “Escape the Drug Pricing Maze” video, Sage the Detective Dog digs up clues on biologics and gene therapies – drugs that offer tremendous value for patients but are some ...
What We’re Watching – May 22
Rowena Itchon – A Memorial Day Tribute 2020 Kerry Jackson – This Doctor Won’t Take Health Insurance – and Charges Just $35 a Visit Meet the Pittsburgh doctor who doesn’t take health care insurance and charges only $35 for most office visits. That makes him a doctor from a different era. But ...
What We’re Watching – May 8
Rowena Itchon – Love in the Time of Coronavirus Watch some of our front line medical personnel battling COVID-19 and helping people stay alive take a much-needed break to recreate the iconic scene from Titanic, with an usual, personal protective equipment-themed twist. Kerry Jackson – Dorothy’s Song, COVID-19 Version Somewhere, ...
Sally Pipes – The Push for Government-Run Health Care During the Coronavirus Crisis
PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies Sally C. Pipes is back to discuss some of the health care challenges that have popped up during the coronavirus crisis, including a renewed push for single-payer and calls for prescription drug price controls and a “Buy America” ...
